| 1 |
30945668 | Association of polymorphisms of CYP11B2 gene -344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension. | 2019 Mar |
2 |
| 2 |
22272064 | Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials. | 2012 |
1 |
| 3 |
21504246 | Telmisartan: a review of its use in cardiovascular disease prevention. | 2011 Apr 16 |
1 |
| 4 |
21576523 | ACP journal club. In hemodialysis patients with CHF, adding telmisartan to standard ACE inhibitors reduced CHD mortality and admissions. | 2011 May 17 |
1 |
| 5 |
21633521 | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection. | 2011 |
1 |
| 6 |
21780334 | Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. | 2011 Jun |
1 |
| 7 |
21788624 | Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. | 2011 Sep |
1 |
| 8 |
19200908 | Telmisartan in high-risk patients intolerant of ACE inhibitors. | 2009 Feb 7 |
1 |
| 9 |
19200909 | Telmisartan in high-risk patients intolerant of ACE inhibitors. | 2009 Feb 7 |
1 |
| 10 |
19200910 | Telmisartan in high-risk patients intolerant of ACE inhibitors. | 2009 Feb 7 |
1 |
| 11 |
19332965 | Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? | 2009 Mar |
2 |
| 12 |
19463125 | [Modern tendencies in the treatment of patients with high risk of development of cardiovascular complications and intolerance to angiotensin converting enzyme inhibitors: value of results of TRANSCEND trial for clinical practice]. | 2009 |
1 |
| 13 |
19491618 | Main results and clinical interpretations from the TRANSCEND study. | 2009 Jun |
1 |
| 14 |
20019467 | [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection]. | 2009 Oct |
1 |
| 15 |
18757085 | Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. | 2008 Sep 27 |
2 |
| 16 |
18997991 | Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients. | 2008 Sep-Oct |
1 |
| 17 |
20409933 | 24-hour powerful blood pressure-lowering: is there a clinical need? | 2008 Jul-Aug |
1 |
| 18 |
23334871 | A New Option for Therapeutic Management of Patients with Cardiovascular Disease : A Closer Look at the ONTARGET Study. | 2008 Apr |
1 |
| 19 |
17583170 | Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. | 2007 |
1 |
| 20 |
16567592 | Telmisartan: the ACE of ARBs? | 2006 May |
1 |
| 21 |
16222898 | Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. | 2005 |
2 |